Newsletter May 2022 No.209
Top News
The spread of novel coronavirus infection (COVID-19) has posed significant challenges to the Japanese pharmaceutical industry, including the need to enhance the country's ability to create new drugs and to build an innovation environment that will serve as the foundation for such efforts. The seminar discussed themes necessary for Japan to continue to be a world-class drug creator, including the development of a drug discovery ecosystem and life science cluster, fostering venture companies and start-ups, strengthening industry-academia-government collaboration, and global mindset. The following is a transcript of the seminar.
Topics
- Report on the "eCTD v4.0 (ICH M8) Notification Revision and Start of Operation Briefing Session
- The "2022 Life Science IP Forum" was held.
-COVID-19 Pandemic Findings on the Innovation Ecosystem: Challenges and Prospects for Solutions - The "Regular Meeting with the German Association of the Research-based Pharmaceutical Industry (vfa)
- The 8th Japan-Thailand Joint Symposium" was held
- Held the "FY2021 Meeting of Compliance Managers and Practitioners
- Held a briefing session on the Cost-Effectiveness Evaluation System
Policy Research Institute page
From JPMA
Establish an environment for innovation that connects with the world